NCT04770870 - Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System | Biotech Hunter

Enrollment

232

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions

Osteoarthritis AnklePost-Traumatic Osteoarthritis of AnkleOsteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)

Interventions

DEVICE

Hintermann Series H3 Total Ankle Replacement System

Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.

Trial Locations (10)

21287

RECRUITING

Department of Orthopedic Surgery, Johns Hopkins Outpatient Center, Baltimore

27560

RECRUITING

Duke Orhtopaedics Arringdon, Morrisville

29425

RECRUITING

MUSC Department of Orthopaedics/Foot and Anke Services, Charleston

33407

RECRUITING

Paley Orthopedic & Spine Institute, West Palm Beach

34233

RECRUITING

Florida Orthopedic Foot & Ankle Center, Sarasota

47710

RECRUITING

Orthopaedic Associates, Evansville

73104

TERMINATED

Dept. of Orthopedic Surgery and Rehabilitation, University of Oklahoma, Oklahoma City

77024

RECRUITING

Spring Branch Podiatry, PLLC, Houston

88310

RECRUITING

New Mexico Bone and Joint Institute, Alamogordo

91345

RECRUITING

Los Angeles Institute of Foot and Ankle Surgery, Mission Hills